Revisiting Prostate Cancer in India: A Genomic View

Ayam Gupta, Prameesha Perera, Nidhi Shukla, Mamta Nehra, Mukesh Sharma, Sneha Mishra, Vikram Singh Chauhan, Babita Malik, Maneesh Kumar Vijay, Suresh Kumar Jatawa, Archana Tiwari, Krishna Mohan Medicherla, Praveen Mathur, Devendra Sharma


In the recent past, there has been a rise in Prostate Cancer (PCa) in Asia, particularly India.  Although systematic reviews on PCa have dealt on the genetics, genomics and the environmental influence in causal of PCa, no predictive analytics in comparing the PCa from Caucasian, American to Asian population was attempted. In this review article, we have attempted to elaborate this aspect of PCa and deliberated on challenges related to next generation sequencing methods of PCa’s manifestation when compared to the west.

Full Text:



Chen SL, Wang SC, Ho CJ, Kao YL, Hsieh TY, Chen WJ, et al. Prostate cancer mortality-to-incidence ratios are associated with cancer care disparities in 35 countries. Sci Rep 2017;7:1–6. doi:10.1038/srep40003.

GLOBOCON. GLOBOCON 2012. (accessed September 6, 2018).

Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol 2008;15:3866–71. doi:10.3892/ol.2015.3556.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–86. doi:10.1002/ijc.29210.

Bashir MN. Epidemiology of prostate cancer_1. Asian Pacific J Cancer Prev 2015;16:5137–41. doi:10.7314/APJCP.2015.16.13.5137.

Wong MCS, Goggins WB, Wang HHX, Fung FDH, Leung C, Wong SYS, et al. Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries. Eur Urol 2016;70:862–74. doi:10.1016/j.eururo.2016.05.043.

Hernández J, Thompson IM. Prostate-specific antigen: A review of the validation of the most commonly used cancer biomarker. Cancer 2004;101:894–904. doi:10.1002/cncr.20480.

Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 1995;87:652–61. doi:10.1093/jnci/87.9.652.

Hwang YW, Kim SY, Jee SH, Kim YN, Nam CM. Soy food consumption and risk of prostate cancer: A meta-analysis of observational studies. Nutr Cancer 2009;61:598–606. doi:10.1080/01635580902825639.

Sinha R, Anderson DE, McDonald SS, Greenwald P. Cancer risk and diet in India. J Postgrad Med 2003;49:222–8.

Tran HN, Udaltsova N, Li Y, Klatsky AL. Low Cancer Risk of South Asians: A Brief Report. Perm J 2018;22:17–095. doi:10.7812/TPP/17-095.

Jain S, Saxena S, Kumar A. Epidemiology of prostate cancer in India. Meta Gene 2014;2:596–605. doi:10.1016/j.mgene.2014.07.007.

Barbieri CE, Bangma CH, Bjartell A, Catto JWF, Culig Z, Grönberg H, et al. The mutational landscape of prostate cancer. Eur Urol 2013;64:567–76. doi:10.1016/j.eururo.2013.05.029.

Stratton MR. Exploring the genomes of cancer cells: Progress and promise. Science (80- ) 2011;331:1553–8. doi:10.1126/science.1204040.

MacConaill LE, Garraway LA. Clinical implications of the cancer genome. J Clin Oncol 2010;28:5219–28. doi:10.1200/JCO.2009.27.4944.

Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161:1215–28. doi:10.1016/j.cell.2015.05.001.

Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012;44:685–9. doi:10.1038/ng.2279.

Barbieri CE, Chinnaiyan AM, Lerner SP, Swanton C, Rubin MA. The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. Eur Urol 2017;71:237–46. doi:10.1016/j.eururo.2016.08.024.

Shen M, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010:1967–2000. doi:10.1101/gad.1965810.GENES.

Heitzer E, Ulz P, Belic J, Gutschi S, Quehenberger F, Fischereder K, et al. Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med 2013;5:30. doi:10.1186/gm434.

Camacho N, Van Loo P, Edwards S, Kay JD, Matthews L, Haase K, et al. Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. PLoS Genet 2017;13:1–28. doi:10.1371/journal.pgen.1007001.

Tomlins SA. Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer. Science (80- ) 2005;310:644–8. doi:10.1126/science.1117679.

Ren S, Wei GH, Liu D, Wang L, Hou Y, Zhu S, et al. Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression [Figure presented]. Eur Urol 2018;73:322–39. doi:10.1016/j.eururo.2017.08.027.

Lin P-C, Giannopoulou EG, Park K, Mosquera JM, Sboner A, Tewari AK, et al. Epigenomic Alterations in Localized and Advanced Prostate Cancer. Neoplasia 2013;15:373-IN5. doi:10.1593/neo.122146.

Chen R, Ren S, Meng T, Aguilar J, Sun Y. Impact of glutathione-S-transferases (GST) polymorphisms and hypermethylation of relevant genes on risk of prostate cancer biochemical recurrence: a meta-analysis. PLoS One 2013;8:e74775. doi:10.1371/journal.pone.0074775.

Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: Implication for diagnosis and treatment. J Natl Cancer Inst 2005;97:103–15. doi:10.1093/jnci/dji010.

Lin X, Tascilar M, Lee WH, Vles WJ, Lee BH, Veeraswamy R, et al. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol 2001;159:1815–26. doi:10.1016/S0002-9440(10)63028-3.

Huppertz I, Attig J, D’Ambrogio A, Easton LE, Sibley CR, Sugimoto Y, et al. iCLIP: Protein-RNA interactions at nucleotide resolution. Methods 2014;65:274–87. doi:10.1016/j.ymeth.2013.10.011.

Giunta CJ. Historical Chemists in Fiction. Biomed. Eng. Comput. Biol., vol. 7s1, 2013, p. 129–42. doi:10.1021/bk-2013-1136.ch008.

Held-Warmkessel J. Contemporary issues in Prostate cancer: A Nursing perspective. 2nd ed. Philadelphia: Jones and Bartlett; 2006.

Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nat Rev Cancer 2008;8:268–78. doi:10.1038/nrc2351.

Liu Y, Hegde P, Zhang F, Hampton G, Jia S. Prostate cancer- a biomarker perspective. Front Endocrinol (Lausanne) 2012;3:72. doi:10.3389/fendo.2012.00072.

Hessels D, Schalken JA. Urinary biomarkers for prostate cancer: A review. Asian J Androl 2013;15:333–9. doi:10.1038/aja.2013.6.

Catalona WJ, Loeb S. Prostate cancer screening and determining the appropriate prostate-specific antigen cutoff values. J Natl Compr Canc Netw 2010;8:265–70. doi:10.6004/jnccn.2010.0017.

Gleason DF. Histologic Grading and Staging of Prostatic Carcinoma. Am J Surg Pathol 1981;5:193–208. doi:10.1108/RPJ-07-2011-0067.

Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. J Am Med Assoc 1998;279:1542–7. doi:10.1001/jama.279.19.1542.

Eckersberger E, Finkelstein J, Sadri H, Margreiter M, Taneja SS, Lepor H, et al. Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials. Rev Urol 2009;11:127–33. doi:10.3909/riu0474.

Meyer P, Zuern C, Hermanns N, Haak T. The association between paternal prostate cancer and type 2 diabetes. J Carcinog 2007;6:1–5. doi:10.1186/1477-3163-6-14.

Baradaran N, Ahmadi H, Salem S, Lotfi M, Jahani Y, Baradaran N, et al. The protective effect of diabetes mellitus against prostate cancer: Role of sex hormones. Prostate 2009;69:1744–50. doi:10.1002/pros.21023.

Pitteloud N, Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson KF, et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005;28:1636–42. doi:10.2337/diacare.28.7.1636.

Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal Predictors of Prostate Cancer: A Meta-Analysis. J Clin Oncol 2000;18:847–847. doi:10.1200/JCO.2000.18.4.847.

Travis RC, Key TJ, Allen NE, Appleby PN, Roddam AW, Rinaldi S, et al. Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2007;121:1331–8. doi:10.1002/ijc.22814.

Hsing AW. Hormones and Prostate Cancer: What’s Next? [Miscellaneous Article]. Public Health 2001;23:42–58.

Will JC, Vinicor F, Calle EE. Is diabetes mellitus associated with prostate cancer incidence and survival? Epidemiology 1999;10:313–8. doi:10.1097/00001648-199905000-00021.

Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997;76:1115–8. doi:10.1038/bjc.1997.520.

Hegele RA, Cao H, Harris SB, Zinman B, Hanley AJG, Anderson CM. Peroxisome proliferator-activated receptor-γ2 P12A and type 2 diabetes in Canadian Oji-Cree. J Clin Endocrinol Metab 2000;85:2014–9. doi:10.1210/jc.85.5.2014.

Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci 2000;97:10990–5. doi:10.1073/pnas.180329197.

Håheim LL. Metabolic syndrome and prostate cancer. Expert Rev Endocrinol Metab 2007;2:633–40. doi:10.1586/17446651.2.5.633.

Barratt J. Collaborative communication: learning from advanced clinical practice patient consultations. Nurs Stand 2018;33:27–32. doi:10.1038/sj.bjc.6601857.

Kovács G, Hoskin P. Interstitial Prostate Brachytherapy. Berlin, Heidelberg: Springer Berlin Heidelberg; 2013. doi:10.1007/978-3-642-36499-0.

Fernandez-Serra A, Casanova-Salas I, Rubio L, Calatrava A, García-Flores M, García-Casado Z, et al. [Update on the diagnosis of PCa in urine. The current role of urine markers]. Arch Esp Urol 2015;68:240–9.

Ploussard G, De La Taille A. Urine biomarkers in prostate cancer. Nat Rev Urol 2010;7:101–9. doi:10.1038/nrurol.2009.261.

Eric Thomas C, Sexton W, Benson K, Sutphen R, Koomen J. Urine collection and processing for protein biomarker discovery and quantification. Cancer Epidemiol Biomarkers Prev 2010;19:953–9. doi:10.1158/1055-9965.EPI-10-0069.

Fujita K, Pavlovich CP, Netto GJ, Konishi Y, Isaacs WB, Ali S, et al. Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology. Hum Pathol 2009;40:924–33. doi:10.1016/j.humpath.2009.01.004.

Bartel DP. MicroRNAs: Target Recognition and Regulatory Functions. Cell 2009;136:215–33. doi:10.1016/j.cell.2009.01.002.

Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol 2012;6:590–610. doi:10.1016/j.molonc.2012.09.006.

Catto JWF, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, et al. MicroRNA in prostate, bladder, and kidney cancer: A systematic review. Eur Urol 2011;59:671–81. doi:10.1016/j.eururo.2011.01.044.

Bryant RJ, Pawlowski T, Catto JWF, Marsden G, Vessella RL, Rhees B, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012;106:768–74. doi:10.1038/bjc.2011.595.

Jackson BL, Grabowska A, Ratan HL. MicroRNA in prostate cancer: functional importance and potential as circulating biomarkers. BMC Cancer 2014;14:930. doi:10.1186/1471-2407-14-930.

Bussemakers MJG, Van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HFM, Schalken JA, et al. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975–9. doi:10.1038/ncb2161.

Gou X, Huang P, Mou C, Luo Y. The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: a systematic review and meta-analysis. Asian J Androl 2014;16:487. doi:10.4103/1008-682X.125390.

Tinzl M, Marberger M, Horvath S, Chypre C. DD3PCA3 RNA analysis in urine - A new perspective for detecting prostate cancer. Eur Urol 2004;46:182–6. doi:10.1016/j.eururo.2004.06.004.

De Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, et al. DD3PCA3, a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002;62:2695–8. doi:10.1016/s0022-5347(01)65160-7.

Wang F, Ren S, Chen R, Lu J, Shi X, Zhu Y, et al. Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer. Oncotarget 2014;5:11091–102. doi:10.18632/oncotarget.2691.

Zhang W, Ren SC, Shi XL, Liu YW, Zhu YS, Jing T Le, et al. A novel urinary long non-coding RNA transcript improves diagnostic accuracy in patients undergoing prostate biopsy. Prostate 2015;75:653–61. doi:10.1002/pros.22949.

Leyten GHJM, Hessels D, Smit FP, Jannink SA, De Jong H, Melchers WJG, et al. Identification of a candidate gene panel for the early diagnosis of prostate cancer. Clin Cancer Res 2015;21:3061–70. doi:10.1158/1078-0432.CCR-14-3334.

Ren S, Wang F, Shen J, Sun Y, Sun Y, Xu W, et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer 2013;49:2949–59. doi:10.1016/j.ejca.2013.04.026.

Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, et al. The genomic complexity of primary human prostate cancer. Nature 2011;470:214–20. doi:10.1038/nature09744.

St. John J, Powell K, Katie Conley-LaComb M, Chinni SR. TMPRSS2-ERG fusion gene expression in prostate tumor cells and its clinical and biological significance in prostate cancer progression. J Cancer Sci Ther 2012;4:94–101. doi:10.4172/1948-5956.1000119.

Mikhaĭlenko DS, Perepechin D V, Apolikhin OI, Efremov GD, Sivkov A V. Markers for non-invasive molecular genetic diagnosis of oncourological diseases. Urologiia 2014:116–20.

Merdan S, Tomlins SA, Barnett CL, Morgan TM, Montie JE, Wei JT, et al. Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy. Cancer 2015;121:4071–9. doi:10.1002/cncr.29611.

Liong ML, Lim CR, Yang H, Chao S, Bong CW, Leong WS, et al. Blood-based biomarkers of aggressive prostate cancer. PLoS One 2012;7:e45802. doi:10.1371/journal.pone.0045802.

Roth C, Schuierer M, Günther K, Buettner R. Genomic structure and DNA binding properties of the human zinc finger transcriptional repressor AP-2rep (KLF12). Genomics 2000;63:384–90. doi:10.1006/geno.1999.6084.

Pasquier L Du. Innate immunity in early chordates and the appearance of adaptive immunity. Comptes Rendus - Biol 2004;327:591–601. doi:10.1016/j.crvi.2004.04.004.

Yeh JH, Sidhu SS, Chan AC. Regulation of a Late Phase of T Cell Polarity and Effector Functions by Crtam. Cell 2008;132:846–59. doi:10.1016/j.cell.2008.01.013.

Kulis M, Esteller M. DNA Methylation and Cancer. Adv. Genet., vol. 70, 2010, p. 27–56. doi:10.1016/B978-0-12-380866-0.60002-2.

Martignano F, Gurioli G, Salvi S, Calistri D, Costantini M, Gunelli R, et al. GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications. Dis Markers 2016;2016:1–6. doi:10.1155/2016/4358292.

Zhao F, Olkhov-Mitsel E, van der Kwast T, Sykes J, Zdravic D, Venkateswaran V, et al. Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance. J Urol 2017;197:335–41. doi:10.1016/j.juro.2016.08.081.

Morgan R, Boxall A, Bhatt A, Bailey M, Hindley R, Langley S, et al. Engrailed-2 (EN2): A tumor specific urinary biomarker for the early diagnosis of prostate cancer. Clin Cancer Res 2011;17:1090–8. doi:10.1158/1078-0432.CCR-10-2410.

Saedi MS, Zhu Z, Marker K, Liu RS, Carpenter PM, Rittenhouse H, et al. Human kallikrein 2 (HK2), but not prostate-specific antigen (PSA), rapidly complexes with protease inhibitor 6 (PI-6) released from prostate carcinoma cells. Int J Cancer 2001;94:558–63. doi:10.1002/ijc.1501.

Xu LL, Stackhouse BG, Florence K, Zhang W, Shanmugam N, Sesterhenn IA, et al. PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. Cancer Res 2000;60:6568–72.

Xu LL, Sun C, Petrovics G, Makarem M, Furusato B, Zhang W, et al. Quantitative expression profile of PSGR in prostate cancer. Prostate Cancer Prostatic Dis 2006;9:56–61. doi:10.1038/sj.pcan.4500836.

Jiang Z, Fanger GR, Woda BA, Banner BF, Algate P, Dresser K, et al. Expression of α-methylacyl-CoA racemase (P504S) in various malignant neoplasms and normal tissues: A study of 761 cases. Hum Pathol 2003;34:792–6. doi:10.1016/S0046-8177(03)00268-5.

Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, Giacherio D, et al. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. JNCI J Natl Cancer Inst 2004;96:834–43. doi:Doi 10.1093/Jnci/Djh145.

Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, et al. B7-H3 ligand expression by prostate cancer: A novel marker of prognosis and potential target for therapy. Cancer Res 2007;67:7893–900. doi:10.1158/0008-5472.CAN-07-1068.

Mahnke K, Ring S, Johnson TS, Schallenberg S, Schönfeld K, Storn V, et al. Induction of immunosuppressive functions of dendritic cellsin vivo by CD4+CD25+ regulatory T cells: Role of B7-H3 expression and antigen presentation. Eur J Immunol 2007;37:2117–26. doi:10.1002/eji.200636841.

Zhao Z, Zeng G, Zhong W. Serum early prostate cancer antigen (EPCA) as a significant predictor of incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia. Prostate 2010;70:1788–98. doi:10.1002/pros.21215.

Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2005;55:74–108. doi:10.3322/canjclin.55.2.74.

Kessler B, Albertsen P. The natural history of prostate cancer. Urol Clin North Am 2003;30:219–26. doi:10.1016/S0094-0143(02)00182-9.

Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, et al. Hereditary prostate cancer: Epidemiologic and clinical features. J Urol 1993;150:797–802. doi:10.1016/S0022-5347(17)35617-3.

Liede A, Karlan BY, Narod SA. Cancer Risks for Male Carriers of Germline Mutations in BRCA1 or BRCA2 : A Review of the Literature. J Clin Oncol 2004;22:735–42. doi:10.1200/JCO.2004.05.055.

Wu D, Ni J, Beretov J, Cozzi P, Willcox M, Wasinger V, et al. Urinary biomarkers in prostate cancer detection and monitoring progression. Crit Rev Oncol Hematol 2017;118:15–26. doi:10.1016/j.critrevonc.2017.08.002.

Velonas VM, Woo HH, dos Remedios CG, Assinder SJ. Current status of biomarkers for prostate cancer. Int J Mol Sci 2013;14:11034–60. doi:10.3390/ijms140611034.

King CJ, Woodward J, Schwartzman J, Coleman DJ, Lisac R, Wang NJ, et al. Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer. Oncotarget 2017;8:111084–95. doi:10.18632/oncotarget.22560.

Ren S, Peng Z, Mao JH, Yu Y, Yin C, Gao X, et al. RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res 2012;22:806–21. doi:10.1038/cr.2012.30.

Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 2011;29:742–9. doi:10.1038/nbt.1914.

Thompson JC, Wood J, Feuer D. Prostate cancer: Palliative care and pain relief. Br Med Bull 2007;83:341–54. doi:10.1093/bmb/ldm018.

Lutz ST, Chow EL, Hartsell WF, Konski AA. A review of hypofractionated palliative radiotherapy. Cancer 2007;109:1462–70. doi:10.1002/cncr.22555.

Thompson JC, Wood J, Feuer D. Prostate cancer: Palliative care and pain relief. Br Med Bull 2007;83:341–54. doi:10.1093/bmb/ldm018.

Zobniw CM, Causebrook A, Fong MK. Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Reports Urol 2014;6:97–105. doi:10.2147/RRU.S29003.